Methods of administering dalbavancin for treatment of skin and soft tissue infections

Abstract

The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of dalbavancin for treatment of a bacterial infection, in particular a Gram-positive bacterial complicated infection of skin and soft tissue. Dosing regimes include once weekly administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection.

1 . A method for treatment of a bacterial infection in a patient having a complicated skin or soft tissue infection, the method comprising the steps of: 
 selecting a patient having a complicated infection of the skin or soft tissue; and    administering a therapeutically effective dose of a pharmaceutical composition comprising dalbavancin.    
     
     
         2 . (canceled)  
     
     
         3 . The method of  claim 1 , wherein the dose is administered intravenously.  
     
     
         4 . The method of  claim 1 , further comprising the step of monitoring a decrease in the complicated infection of the skin or soft tissue.  
     
     
         5 . (canceled)  
     
     
         6 . The method of  claim 1 , further comprising administering at least one subsequent dose.  
     
     
         7 . The method of  claim 6 , wherein the at least one subsequent dose is administered at least 5 to 10 days after the first therapeutically effective dose.  
     
     
         8 . The method of  claim 6 , wherein the at least one subsequent dose is administered about one week after the first therapeutically effective dose.  
     
     
         9 . The method of  claim 6 , further comprising adjusting the at least one subsequent dose based on the monitored decrease in the infection.  
     
     
         10 . The method of  claim 1 , wherein the therapeutically effective dose is about 1100 mg.  
     
     
         11 . The method of  claim 1 , wherein the therapeutically effective dose is about 1000 mg.  
     
     
         12 . The method of  claim 6 , wherein the at least one subsequent dose is about 500 mg.  
     
     
         13 . (canceled)  
     
     
         14 . The method of  claim 6 , wherein the initial therapeutically effective dose comprises at least twice as much dalbavancin as the at least one subsequent dose.  
     
     
         15 - 33 . (canceled)  
     
     
         34 . A method for treatment of a bacterial infection in a patient having a complicated skin or soft tissue infection, the method comprising the steps of: 
 selecting a patient having a complicated infection of the skin or soft tissue caused by a gram positive bacteria;    administering a therapeutically effective dose of a pharmaceutical composition comprising dalbavancin; and    administering at least one subsequent therapeutically effective dose of a pharmaceutical composition comprising dalbavancin.    
     
     
         35 - 47 . (canceled)  
     
     
         48 . The method of  claim 34 , wherein the at least one subsequent dose is administered at least 5 to 10 days after the first therapeutically effective dose.  
     
     
         49 . The method of  claim 34 , wherein the at least one subsequent dose is administered about one week after the first therapeutically effective dose.  
     
     
         50 . The method of  claim 34 , wherein the at least one subsequent dose is about 500 mg.  
     
     
         51 . The method of  claim 34 , wherein the therapeutically effective dose is about 1000 mg and the at least one subsequent dose is about 500 mg.  
     
     
         52 . The method of  claim 34 , wherein the therapeutically effective dose comprises at least twice as much dalbavancin as the at least one subsequent dose.  
     
     
         53 . (canceled)  
     
     
         54 . A method for treatment of a bacterial infection in a patient having a complicated skin or soft tissue infection comprising administering to said patient a pharmaceutically effective amount of dalbavancin according to a regimen having a once-weekly dosing interval.  
     
     
         55 . The method of  claim 54 , wherein the pharmaceutically effective amount is administered by a method selected from the group consisting of parenteral, intramuscular, intravenous, subcutaneous, intraperitoneal, and intrathecal.  
     
     
         56 . The method of  claim 54 , wherein the pharmaceutically effective amount is about 1100 mg.  
     
     
         57 . The method of  claim 54 , wherein the pharmaceutically effective amount is about 1000 mg.  
     
     
         58 . The method of  claim 54 , wherein the regimen having a once-weekly dosing interval has an initial dose and at least one subsequent dose.  
     
     
         59 . The method of  claim 58 , wherein the at least one subsequent dose is administered at least 5 to 10 days after the initial dose.  
     
     
         60 . The method of  claim 58 , wherein the at least one subsequent dose is administered about one week after the initial dose.  
     
     
         61 . The method of  claim 58 , wherein the pharmaceutically effective amount of the initial dose is about 1000 mg.  
     
     
         62 . The method of  claim 58 , wherein the pharmaceutically effective amount of the at least one subsequent dose is about 500 mg.  
     
     
         63 . The method of  claim 58 , wherein the pharmaceutically effective amount of the initial dose comprises at least twice as much dalbavancin as the at least subsequent dose.  
     
     
         64 . The method of  claim 58 , wherein the pharmaceutically effective amount of the initial dose comprises at least three times as much dalbavancin as the at least subsequent dose.